Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular EventsEconomic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

被引：0

作者：

Peter K. Schädlich

Josef Georg Brecht

Badrudin Rangoonwala

Eduard Huppertz

机构：

[1] InForMed GmbH — Outcomes Research and Health Economics,

[2] Bureau Itzehoe,undefined

[3] Aventis Pharma Deutschland GmbH,undefined

来源：

PharmacoEconomics | 2004年 / 22卷

关键词：

Ramipril; Target Variable; Statutory Health Insurance; Heart Outcome Prevention Evaluation; Microvascular Diabetic Complication;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well as the incidence of costly cardiovascular events, such as myocardial infarction, revascularisation, stroke, cardiac arrest, hospitalisation due to heart failure and worsening angina pectoris, new-onset diabetes mellitus and microvascular diabetic complications.

引用

页码：955 / 973

页数：18

共 50 条

[31] Secondary Prevention via Case Managers in Stroke Patients: A Cost-Effectiveness Analysis of Claims Data from German Statutory Health Insurance Providers
Duevel, Juliane A.
Gruhn, Sebastian
Grosser, John
Elkenkamp, Svenja
Greiner, Wolfgang
HEALTHCARE, 2024, 12 (11)
[32] Beneficial effects of Ramipril on cardiovascular events in high-risk patients older than 75 years of age: Secondary outcomes from the HOPE trial
Bosch, J
Probstfield, J
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 154A - 154A
[33] Economic evaluation of transesophageal echocardiography (TEE) guided cardioversion in the anticoagulation in cardioversion using enoxaparin (ACE) trial from the perspective of statutory health insurance (SHI) in Germany
Schädlich, PK
Lehmacher, W
Huppertz, E
Grewe, R
Brecht, JG
VALUE IN HEALTH, 2004, 7 (06) : 696 - 696
[34] The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
Kjeldsen, Sverre E.
Narkiewicz, Krzysztof
Burnier, Michel
Oparil, Suzanne
BLOOD PRESSURE, 2020, 29 (01) : 1 - 2
[35] Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance (vol 50, pg 24, 2005)
Hoegy, Barbara
Keinecke, Heinz-Otto
Borte, Michael
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (02): : 203 - 203
[36] Economic evaluation of medically occupationally orientated rehabilitation in patients with musculoskeletal disorders -: A cost-benefit analysis from the perspective of the German statutory pension insurance scheme
Streibelt, M.
Blume, C.
Thren, K.
Mueller-Fahnnow, W.
REHABILITATION, 2008, 47 (03) : 150 - 157
[37] Cost-effectiveness of treating by simvastatin 40 mg/day high vascular risk patients: An economic evaluation based on the heart protection study
Fagnani, F
Lafuma, A
Souchet, T
VALUE IN HEALTH, 2003, 6 (03) : 320 - 320
[38] Cost-effectiveness of treating by simvastatin 40 mg/day high vascular risk patients: An economic evaluation based on the heart protection study
Fagnani, F
Lafuma, A
Souchet, T
VALUE IN HEALTH, 2003, 6 (06) : 657 - 657
[39] Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey
Burstein, Barry
Altobelli, Kathleen K.
Williams, Ken
Cannon, Christopher P.
Pencina, Michael J.
Sniderman, Allan D.
Thanassoulis, George
CIRCULATION, 2017, 136 (19) : 1860 - 1862
[40] Secondary Prevention via Case Managers in Stroke Patients: A Cost-Effectiveness Analysis of Claims Data from German Statutory Health Insurance Providers (vol 12, 1157, 2024)
Duevel, Juliane A.
Gruhn, Sebastian
Grosser, John
Elkenkamp, Svenja
Greiner, Wolfgang
HEALTHCARE, 2024, 12 (16)

← 1 2 3 4 5 →